Ogsiveo (Nirogacestat) for Desmoid Tumor

Overview
Ogsiveo is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with progressing desmoid tumors who require systemic therapy. Ogsiveo is also known by its drug name, nirogacestat​​​​.

Nirogacestat functions as a gamma secretase inhibitor, which is thought to work by inhibiting the Notch signaling pathway that plays a role in the development of desmoid tumors. By blocking this pathway, nirogacestat may help to limit or reduce the growth of desmoid tumors​​.

How do I take it?
Ogsiveo is administered orally in the form of tablets twice daily, with or without food. The medication should be taken exactly as prescribed by a health care provider​​.

Side effects
Common side effects of Ogsiveo include diarrhea, ovarian toxicity, rash, nausea, fatigue, inflammation of the mouth and lips, headache, abdominal pain, cough, hair loss, upper respiratory tract infection, and difficulty breathing​​.

Rare but serious side effects may include impaired female fertility or fetal harm, abnormal liver levels, some types of skin cancer, and severe diarrhea. 

For more information about this treatment, visit:

Ogsiveo (Nirogacestat) — SpringWorks Therapeutics 

Label: Ogsiveo — Nirogacestat Tablet, Film Coated — DailyMed

Desmoid Tumor: Types of Treatment — Cancer.Net